about
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentOutcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults.Lipid profile in HIV/AIDS patients in NigeriaMicroalbuminuria in HIV infection.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Nevirapine in the treatment of HIV.Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice.Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases.First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.2'-Deoxythymidine adducts from the anti-HIV drug nevirapine.Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.From lipodystrophy to cardiovascular disease: new insight into the management of HIV infection
P2860
Q24803596-DC5E99C8-50FB-4786-AFB0-AD1CE9003DF0Q33378805-34163A84-E024-4C92-950A-1C4CCF90736EQ33850152-69507782-B5F1-4FC7-8FD9-881EC5F23005Q33936089-BFCDF51F-DFB9-4350-A8D1-08564519C87EQ34206446-5E265B15-704C-4EFE-B201-8E26B8A34C05Q35293817-D8DAAF27-69C5-4A5C-83C6-09E56B125C35Q35567828-55DB862B-F36F-4492-9E7D-38290892E29FQ35917412-FD9B2739-D898-47C5-A05C-F67827935BDBQ35926011-2B0A529A-62C4-4E57-904B-8D9A9124D883Q36223917-32865AE0-1162-467D-8473-090AC3611B4BQ37370783-B5E7FD21-FEDC-4252-98F7-ADD1745BF61EQ37541814-C07D5D10-D06E-4736-844B-28E7DFD16F4DQ43937394-4C6BC0E0-BC9B-4789-B9FD-0F9D4F35A493Q46731348-35ECCAE8-492E-49CA-9398-CC5BD7CDABBAQ51008407-062E8E85-1664-44E5-B3C7-3D043F642F4DQ58798012-19606AC4-40AA-481C-8DFB-9FEC546B5E3C
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Impact of nevirapine on lipid metabolism.
@ast
Impact of nevirapine on lipid metabolism.
@en
type
label
Impact of nevirapine on lipid metabolism.
@ast
Impact of nevirapine on lipid metabolism.
@en
prefLabel
Impact of nevirapine on lipid metabolism.
@ast
Impact of nevirapine on lipid metabolism.
@en
P2093
P1476
Impact of nevirapine on lipid metabolism.
@en
P2093
Eugenia Negredo
Marc van der Valk
Peter Reiss
P304
P356
10.1097/00126334-200309011-00012
P407
P478
34 Suppl 1
P577
2003-09-01T00:00:00Z